ABSTRACT
Objective: Despite demonstrating improvements in cardiovascular disease, kidney disease, and survival outcomes, guideline-directed antihyperglycemic medications such as sodium-glucose cotransporter 2 inhibitors (SGLT2i) and glucagon-like-peptide-1 receptor agonists (GLP1-RA), are underutilized. Many obstacles constrain their use including lack of systematic provider and patient education, concern for medication side effects, and patient affordability. Methods: We designed a multimodality, systems-based approach to address these challenges with the goal of increasing medication utilization across the largest healthcare system in New York State. This multispecialty collaborative included provider and patient education, an electronic health record-enabled platform to identify eligible patients, and access to pharmacists for medication guidance and addressing insurance coverage barriers. Surveys were administered following grand rounds lectures and knowledge-based questionnaires were given before and after case-based sessions for housestaff, with results analyzed using a two-sided Student's t-test. Rates of first prescriptions of SGLT2i/GLP1-RA in combined and individual analyses were compared between the pre- and post-education periods (6 months prior to 3/31/2021 and 6 months post 8/19/2021), and the change in prescriptions per 100 eligible-visits was assessed using the incidence density approach. Results: Among grand rounds participants, 69.3% of respondents said they would make changes to their clinical practice. Knowledge increased by 14.7% (p-value <0.001) among housestaff following case-based sessions. An increase in SGLT2i/GLP1-RA prescribing was noted for eligible patients among internal medicine, cardiology, nephrology, and endocrinology providers, from 11.9 per 100 eligible visits in the pre-education period to 14.8 in the post-education period (absolute increase 2.9 [24.4%], incidence risk ratio 1.24 [95% CI 1.18-1.31]; p-value <0.001). Increases in prescribing rates were also seen among individual medical specialties. Conclusions: Our "Beyond Diabetes" initiative showed an improvement in provider knowledge-base and was associated with a modest, but statistically significant increase in the use of SGLT2i and GLP1-RA throughout our healthcare system.
ABSTRACT
The objective of this scientific statement is to evaluate contemporary evidence that either supports or refutes the conclusion that aggressive low-density lipoprotein cholesterol lowering or lipid lowering exerts toxic effects on the brain, leading to cognitive impairment or dementia or hemorrhagic stroke. The writing group used literature reviews, references to published clinical and epidemiology studies, clinical and public health guidelines, authoritative statements, and expert opinion to summarize existing evidence and to identify gaps in current knowledge. Although some retrospective, case control, and prospective longitudinal studies suggest that statins and low-density lipoprotein cholesterol lowering are associated with cognitive impairment or dementia, the preponderance of observational studies and data from randomized trials do not support this conclusion. The risk of a hemorrhagic stroke associated with statin therapy in patients without a history of cerebrovascular disease is nonsignificant, and achieving very low levels of low-density lipoprotein cholesterol does not increase that risk. Data reflecting the risk of hemorrhagic stroke with lipid-lowering treatment among patients with a history of hemorrhagic stroke are not robust and require additional focused study.
Subject(s)
Anticholesteremic Agents , Dementia , Hemorrhagic Stroke , Hydroxymethylglutaryl-CoA Reductase Inhibitors , Stroke , Humans , American Heart Association , Anticholesteremic Agents/adverse effects , Brain , Cholesterol, LDL , Dementia/diagnosis , Dementia/epidemiology , Dementia/prevention & control , Ezetimibe , Hemorrhagic Stroke/diagnosis , Hemorrhagic Stroke/epidemiology , Hemorrhagic Stroke/prevention & control , Hydroxymethylglutaryl-CoA Reductase Inhibitors/adverse effects , Prospective Studies , Retrospective Studies , Stroke/diagnosis , Stroke/epidemiology , Stroke/prevention & controlABSTRACT
Compound heterozygous familial hypercholesterolemia patients are phenotypically similar to homozygous familial hypercholesterolemia patients, present with significant elevations of low-density lipoprotein cholesterol, and are at risk of cardiovascular disease. Although new treatment options are emerging, the stepwise approach to the use of different therapies has not been well described. (Level of Difficulty: Intermediate.).
ABSTRACT
Although statin therapy is a primary treatment to prevent cardiac allograft vasculopathy (CAV), its use may be delayed due to pharmacologic interactions in the early post-transplant period among heart transplant (HT) recipients with hepatitis C virus positive (HCV+) donors. Further examination of the possible benefits of early, nonstatin lipid-lowering therapies (LLT), such as PCSK9 inhibitors (PCSK9i), among this specific subset of transplant recipients is therefore becoming increasingly important. We report a 60-year-old man who received a HT from a HCV+ donor for end-stage ischemic cardiomyopathy. In the early post-transplant period, there was concern for drug-drug interactions between statin, immunosuppressant, and direct acting antiviral (DAA) therapy. In addition, prior to transplant, he reported statin-associated muscle symptoms in response to multiple statins, which persisted despite attempts to re-challenge and use an every-other-day dosing strategy. Therefore, the patient was started on PCSK9i therapy after transplantation and while receiving curative DAA therapy for HCV. As the number of HT recipients of HCV+ donors continue to rise, investigation into the safety and benefits of early use of PCSK9i for the reduction of CAV and improved cardiovascular and mortality outcomes should be pursued.
Subject(s)
Graft Rejection/drug therapy , Heart Transplantation/trends , Hepatitis C/drug therapy , Living Donors , PCSK9 Inhibitors/administration & dosage , Proprotein Convertase 9/metabolism , Graft Rejection/diagnosis , Graft Rejection/immunology , Hepatitis C/diagnosis , Hepatitis C/immunology , Humans , Male , Middle AgedABSTRACT
A left ventricular (LV) false tendon is a frequently visualized structure in echocardiography with unclear clinical significance. We present the case of a false tendon serving as a nidus for thrombus in a post-orthotopic heart transplantation patient. Three-dimensional transthoracic echocardiography (3DTTE) was utilized to visualize a LV mass and facilitate its identification as a thrombus as well as the surrounding structures. Using datasets from 3DTTE, the lack of ventricular wall attachment and circumferential formation of the thrombus around the false tendon was identified. Serial imaging demonstrated resolution of the thrombus with anticoagulation.
Subject(s)
Heart Diseases/diagnosis , Heart Transplantation , Thrombosis/diagnosis , Echocardiography, Three-Dimensional/methods , Heart Defects, Congenital/surgery , Heart Diseases/etiology , Heart Ventricles , Humans , Magnetic Resonance Imaging, Cine , Male , Middle Aged , Thrombosis/etiologyABSTRACT
In addition to aggressive lifestyle and nonlipid risk factor modification, statin therapy improves cardiovascular disease outcomes following acute coronary syndromes. Despite established benefits of treatment, contemporary registries reveal substantial underutilization of and nonadherence to statin therapy for secondary prevention. In randomized controlled trials investigating statin therapy, including moderate-intensity statin plus ezetimibe therapy, rates of nonadherence are reported in up to 40% of subjects. Durable strategies to address gaps in lipid lowering for secondary prevention are essential to maximize reduction in cardiovascular disease risk.
Subject(s)
Acute Coronary Syndrome/complications , Cardiovascular Diseases/prevention & control , Guideline Adherence , Hydroxymethylglutaryl-CoA Reductase Inhibitors/therapeutic use , Practice Guidelines as Topic , Comorbidity , Drug Therapy, Combination , Humans , Hydroxymethylglutaryl-CoA Reductase Inhibitors/administration & dosage , Hydroxymethylglutaryl-CoA Reductase Inhibitors/adverse effects , Life Style , Randomized Controlled Trials as Topic , Socioeconomic FactorsABSTRACT
The association of atrial fibrillation (AF) with ischemic stroke has long been recognized; yet, the pathogenic mechanisms underlying this relationship are incompletely understood. Clinical schemas, such as the CHA2DS2-VASc (congestive heart failure, hypertension, age ≥ 75 years, diabetes mellitus, stroke/transient ischemic attack, vascular disease, age 65 to 74 years, sex category) score, incompletely account for thromboembolic risk, and emerging evidence suggests that stroke can occur in patients with AF even after sinus rhythm is restored. Atrial fibrosis correlates with both the persistence and burden of AF, and gadolinium-enhanced magnetic resonance imaging is gaining utility for detection and quantification of the fibrotic substrate, but methodological challenges limit its use. Factors related to evolution of the thrombogenic fibrotic atrial cardiomyopathy support the view that AF is a marker of stroke risk regardless of whether or not the arrhythmia is sustained. Antithrombotic therapy should be guided by a comprehensive assessment of intrinsic risk rather than the presence or absence of AF at a given time.
Subject(s)
Atrial Fibrillation/complications , Cardiomyopathies/complications , Heart Atria/pathology , Stroke/etiology , Thromboembolism/complications , Atrial Fibrillation/etiology , Cardiomyopathies/diagnosis , Cardiomyopathies/etiology , Fibrosis/complications , Fibrosis/diagnosis , Fibrosis/etiology , Forecasting , Humans , Risk Factors , Signal Transduction , Thromboembolism/etiologyABSTRACT
Triglycerides represent 1 component of a heterogeneous pool of triglyceride-rich lipoproteins (TGRLs). The reliance on triglycerides or TGRLs as cardiovascular disease (CVD) risk biomarkers prompted investigations into therapies that lower plasma triglycerides as a means to reduce CVD events. Genetic studies identified TGRL components and pathways involved in their synthesis and metabolism. We advocate that only a subset of genetic mechanisms regulating TGRLs contribute to the risk of CVD events. This "omic" approach recently resulted in new targets for reducing CVD events.
Subject(s)
Atherosclerosis/metabolism , Cardiovascular Diseases/metabolism , Lipoproteins/metabolism , Triglycerides/metabolism , Atherosclerosis/genetics , Atherosclerosis/prevention & control , Cardiovascular Diseases/genetics , Cardiovascular Diseases/prevention & control , Fasting , Fatty Acids, Omega-3/blood , Fatty Acids, Omega-3/therapeutic use , Genetic Variation , Humans , Hydroxymethylglutaryl-CoA Reductase Inhibitors/therapeutic use , Hypertriglyceridemia/diagnosis , Hypertriglyceridemia/drug therapy , Inflammation/metabolism , Intestinal Mucosa/metabolism , Liver/metabolism , Postprandial Period , Sequence Analysis, DNAABSTRACT
BACKGROUND: Chronotropic incompetence is defined as the inability to reach 80% of heart rate (HR) reserve or 80% of the maximally predicted HR during exercise. The presence of chronotropic incompetence is associated with reduced peak oxygen consumption, and rate-responsive pacing therapy is under investigation to improve exercise capacity in heart failure (HF). However, uncertainty exists about whether chronotropic incompetence and reduced exercise tolerance in HF are attributable to ß-blockade. METHODS AND RESULTS: Subjects with HF and receiving long-term ß-blocker therapy underwent cardiopulmonary exercise tolerance testing under 2 conditions in random sequence: (1) after a 27-hour washout period (Off-BB) and (2) 3 hours after ß-blocker ingestion (On-BB). Norepinephrine levels were drawn at rest and at peak exercise. ß1-response to norepinephrine was assessed using the chronotropic responsiveness index: ΔHR/Δlog norepinephrine. Nineteen patients with systolic HF (left ventricular ejection fraction, 22.8±7.7%) were enrolled. Mean age was 49.4±12.3 years. Average carvedilol equivalent dose was 29.1±17.0 mg daily. Peak HR off/on ß-blockers was 62.7±18.7% and 51.4±18.2% HR reserve (P<0.01) and 79.1±11.0% and 70.3±12.3% maximally predicted HR (P<0.01). For the Off-BB and On-BB conditions, the respiratory exchange ratios were 1.05±0.06 and 1.05±0.10 (P=0.77), respectively, confirming maximal and near identical effort in both conditions. The peak oxygen consumption was 16.6±3.34 and 15.9±3.31 mL/kg/min (P=0.03), and the chronotropic responsiveness index was 19.3±7.2 and 16.2±7.1 (P=0.18). CONCLUSIONS: Acute ß-blocker cessation does not normalize the chronotropic response to exercise in patients with advanced HF and chronotropic incompetence.
Subject(s)
Adrenergic beta-Antagonists/administration & dosage , Exercise Tolerance/drug effects , Heart Failure/drug therapy , Heart Rate/drug effects , Adult , Analysis of Variance , Biomarkers/blood , Bisoprolol/administration & dosage , Carbazoles/administration & dosage , Carvedilol , Drug Administration Schedule , Exercise Test , Female , Heart Failure/blood , Heart Failure/diagnosis , Heart Failure/physiopathology , Humans , Male , Metoprolol/administration & dosage , Middle Aged , New York City , Norepinephrine/blood , Oxygen Consumption/drug effects , Propanolamines/administration & dosage , Prospective Studies , Respiration/drug effects , Time FactorsABSTRACT
In the embryonic kidney, progenitors in the metanephric mesenchyme differentiate into specialized renal epithelia in a defined sequence characterized by the formation of cellular aggregates, conversion into polarized epithelia and segmentation along a proximal-distal axis. This sequence is reiterated throughout renal development to generate nephrons. Here, we identify global transcriptional programs associated with epithelial differentiation utilizing an organ culture model of rat metanephric mesenchymal differentiation, which recapitulates the hallmarks of epithelialization in vivo in a synchronized rather than reiterative fashion. We observe activation of multiple putative targets of beta-catenin/TCF/Lef-dependent transcription coinciding with epithelial differentiation. We show in cultured explants that isolated activation of beta-catenin signaling in epithelial progenitors induces, in a TCF/Lef-dependent manner, a subset of the transcripts associated with epithelialization, including Pax8, cyclin D1 (Ccnd1) and Emx2. This is associated with anti-apoptotic and proliferative effects in epithelial progenitors, whereas cells with impaired TCF/Lef-dependent transcription are progressively depleted from the epithelial lineage. In vivo, TCF/Lef-responsive genes comprise a conserved transcriptional program in differentiating renal epithelial progenitors and beta-catenin-containing transcriptional complexes directly bind to their promoter regions. Thus, beta-catenin/TCF/Lef-mediated transcriptional events control a subset of the differentiation-associated transcriptional program and thereby participate in maintenance, expansion and stage progression of the epithelial lineage.
Subject(s)
Cell Differentiation/genetics , Epithelial Cells/cytology , Kidney/embryology , Mesenchymal Stem Cells/cytology , TCF Transcription Factors/physiology , beta Catenin/physiology , Animals , Base Sequence , Binding Sites , Cells, Cultured , Cluster Analysis , Consensus Sequence , Gene Expression Profiling , Gene Expression Regulation, Developmental , Molecular Sequence Data , Oligonucleotide Array Sequence Analysis , Rats , Sequence Homology, Nucleic AcidABSTRACT
During embryonic development, the structures of the nephron from the glomerulus to distal tubule derive from the metanephric mesenchyme. The mesenchymal cells change their cell type and produce highly organized epithelia under the influence of signals from the ureteric bud. The morphological sequence of this conversion includes the formation of a corona of mesenchymal cells surrounding the tips of the ureteric bud, followed by the development of a pre-tubular aggregate, which evolves into preliminary forms of the segmented nephron. Currently, these stages are largely based on histomorphologic criteria and expression of marker molecules. However, to dissect the effects of inductive signals from the ureteric bud in more detail, a sophisticated readout of stages in the conversion process is required, based on the onset of epithelial polarity and the occurrence of vectorial transport. In this review, we discuss some of the new approaches in establishing the staging of the conversion process.